Eiken Chemical Co., Ltd. · TSE:4549
Eiken Chemical — FY2009 Earnings Presentation
16 slides from Eiken Chemical's earnings presentation, Apr 28, 2010
Slide 1: The business performance briefing for the term ended Mar. 2010 (72nd term)
The business performance briefing for the term ended Mar. 2010 (the 72nd term) (Apr. 2009-Mar. 2010) EIKEN CHEMICAL CO., LTD. Apr. 28, 2010 EIKEN CHEMICAL CO., LTD. 1 Contents ◆ Operating results for the term ended Mar. 2010 (the 72nd term) ◆ Primary strategies for the term ended Mar. 2010 (the 72nd
Slide 2: Operating Results for the term ended Mar. 2010
Operating Results for the term ended Mar. 2010 (the 72nd term) EIKEN CHEMICAL CO., LTD Consolidated performance for the term ended Mar. 2010 (the 72nd term) (Millions of yen) Term ended Mar. 2010 Difference from target value YoY change Target value Actual results Ratio Difference Ratio Difference Ne
Slide 3: Consolidated sales by product category: OC and immunological reagents
Consolidated sales for product category (Millions of yen) Fecal occult blood Term ended Mar. 2008 Term ended Mar. 2009 Term ended Mar. 2010 diagnostic reagents (OC) 5,149 5,505 5,826 5,826 ● 5.8% increase from the 5,505 5,149 corresponding term in the previous year ● The sales of fecal occult blood
Slide 4: Consolidated sales by product category: microbiological and dry chemistry reagents
Consolidated sales for product category (Millions of yen) Term ended Mar. 2008 Term ended Mar. 2009 Term ended Mar. 2010 Microbiological reagents 4,421 4,472 4,449 ● 0.5% decrease from the 4,421 4,472 4,449 corresponding term in the previous year ● Enhancement of sales promotion of Pourmedia ● Aggra
Slide 5: Consolidated sales by product category: clinical chemistry and medical devices
Consolidated sales for product category (Millions of yen) Term ended Mar. 2008 Term ended Mar. 2009 Term ended Mar. 2010 Clinical chemistry reagents 972 934 864 ● 7.5% decrease from the 972 934 corresponding term in the 864 previous year ● Decrease in the use of reagents per test ● Decline in market
Slide 6: Industry products and consolidated overseas sales
Consolidated sales for product category (Millions of yen) Industry products (Culture Term ended Mar. 2008 Term ended Mar. 2009 Term ended Mar. 2010 media for equipment, food and environment category) 2,765 2,678 2,552 2,765 ● 4.7% decrease from the 2,678 corresponding term in the 2,552 previous year
Slide 7: Indicators for consolidated net sales and profit; SG&A and gross margin
Indicators for consolidated net sales and profit Net sales (Millions of yen) Operating income (Millions of yen) - ◆ - Operating margin 26,841 2,050 ratio 25,223 26,113 1,902 1,828 8.1% 7.0% 7.1% Term ended Mar. 2008 Term ended Mar. 2009 Term ended Mar. 2010 Term ended Mar. 2008 Term ended Mar. 2009
Slide 8: R&D cost and investment in equipment; Consolidated cash flows
R&D cost and investment in equipment (consolidated) First half Full year R&D cost Investment in Depreciation and equipment amortization (Millions of yen) (Millions of yen) (Millions of yen) 2,032 1,924 1,754 922 859 886 790 690 606 863 1,018 927 342 438 532 371 398 444 Term ended Term ended Term end
Slide 9: Consolidated balance sheets
Consolidated balance sheets (Millions of yen) Term ended Mar. 2010 Main reasons of increase/decrease Term ended Mar. 2009 Current liabilities ●Current assets Current liabilities 8,763 - Cash and bank deposits 1,618 8,038 - Notes and account receivable 471 Fixed liabilities - Inventories (748) Fixed
Slide 10: Primary strategies for the 72nd term: globalization
Primary strategies for the term ended Mar. 2010 (the 72nd term) ◆ Promotion of globalization ・ Enhancement of the sales promotion for the core product OC and the expansion of target regions - Market cultivation in Europe, the U.S., Australia, and South America, etc. ・ Operation of the Molecular gene
Slide 11: Primary strategies: productivity, ISO14001, risk control
Primary strategies for the term ended Mar. 2010 (the 72nd term) ◆ Efforts for improving productivity ・ Promotion of organizational optimization and business streamlining after the integration of the head office ・ Reduction in outsourcing cost and appropriate staffing by conducting distribution tasks
Slide 12: Primary strategies and earnings forecast for the 73rd term
Primary strategies and earnings forecast for the term ending Mar. 2011 (the 73rd term) EIKEN CHEMICAL CO., LTD Primary strategies and earnings forecast for the term ending Mar. 2011 (the 73rd term) 1. Securing of sales and profit Inside Japan ・ Enhancement of sales promotion of our main products ・ P
Slide 13: Global business expansion
Primary strategies and earnings forecast for the term ending Mar. 2011 (the 73rd term) Global business expansion ◆ Further expansion of OC ・ Measures for the screening in Europe (Austria, Czech, and France) ・ Retry for the screening in Australia ・ U.S.: To target large-scale centers (Kaiser and LabC
Slide 14: Strengthening of R&D
Primary strategies and earnings forecast for the term ending Mar. 2011 (the 73rd term) 2. Strengthening of R&D ◆ Acceleration of product development ・ Promotion of the development of LAMP reagents ・ Improvement of products by brushing up existing technologies ◆ FIND business (examination for tubercu
Slide 15: Consolidated earnings forecast for the term ending Mar. 2011
Consolidated earnings forecast for the term ending Mar. 2011 (the 73rd term) Target value (Millions of yen) Consolidated Non-consolidated Amount Ratio [%] YoY change [%] Amount Ratio [%] YoY change [%] Net sales 27,080 100.0 100.9 27,050 100.0 100.8 Operating income 2,040 7.5 107.2 2,010 7.4 101.2 O
Slide 16: EIKEN CHEMICAL CO., LTD.
EIKEN CHEMICAL CO., LTD. We protect the health of the public through health care services http://www.eiken.co.jp EIKEN CHEMICAL CO., LTD. 31 Notes This document is not the disclosed reference for financial instruments and exchange. Its accuracy and integrity are not guaranteed. The estimates, etc. w